Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10%

“We felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success,” Martin Holst Lange, Novo’s R&D chief, said on Monday.